Document Detail

Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin.
MedLine Citation:
PMID:  23187978     Owner:  NLM     Status:  Publisher    
BACKGROUND: Given the significant side-effects and healthcare costs associated with telaprevir- or boceprevir-combination therapy, identifying patients likely to respond to dual therapy peg-interferon (Peg-IFN)/ribavirin is highly desirable. Since the perception of how large the pool of patients who may achieve rapid virologic response (RVR) is vaguely ascertained, we searched the literature for this information. METHODS: Studies on patients treated with Peg-IFN/ribavirin were identified by searching MEDLINE and analyzed by meta-analysis. The primary end point was weighted estimates of RVR. The influence on race/ethnicity, baseline viremia, type of Peg-IFN, ribavirin dosage, and significant hepatic fibrosis on the results was evaluated. RESULTS: Across 38 studies on 13,219 patients, the fraction of RVR patients was 19.6 %. The only baseline factor influencing RVR was race/ethnicity, with higher rates in Asian (26.7 %) and Caucasian patients (22.5 %). Of the 1,735 RVR patients, 85.1 % attained sustained virologic response (SVR). In these, SVR was influenced by ribavirin dose (86.8 vs. 72.8 % for high or low), type of Peg-IFN (91.8 % for alpha-2b vs. 82.9 % for alpha-2a), and treatment duration (91.7 % for 48 weeks vs. 79.4 % for 24 weeks). CONCLUSIONS: One fifth to one fourth of hepatitis C virus genotype 1 (HCV-1) patients can be safely treated with dual therapy of Peg-IFN/ribavirin, and may be spared from cost and inconvenience of regimens considering the addition of HCV protease inhibitors.
A Andriulli; A Iacobellis; M R Valvano; F Spirito; A Ippolito; F Bossa; F Terracciano; R Fontana; G Niro
Related Documents :
22402498 - Impact of a thoracic nurse-led chest drain clinic on patient satisfaction.
16335628 - Managing eating disorders in the natural environment: intensive vs. limited programs.
22536478 - Successful long term eradication of factor viii inhibitor in patients with acquired hae...
22420838 - Assessment of the safety and feasibility of administering anti-pyretic therapy in criti...
24955978 - Admission cell free dna levels predict 28-day mortality in patients with severe sepsis ...
20610618 - Private sector treatment centres are treating less complex patients than the nhs.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-28
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  -     ISSN:  1573-2568     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, viale Cappuccini 1, 71013, San Giovanni Rotondo, Italy,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synthesis of peptide-grafted comb polypeptides via polymerisation of NCA-peptides.
Next Document:  A Randomized Controlled Trial to Engage in Care of Adolescent Emergency Department Patients With Men...